ARHGAP45

ARHGAP45, also known as Rho GTPase-activating protein 45, is a protein that plays a crucial role in the regulation of the Rho family of GTPases. It functions as a GTPase-activating protein (GAP), accelerating the hydrolysis of GTP to GDP, thereby inactivating Rho GTPases. This protein is involved in various cellular processes, including cell morphology, motility, proliferation, and apoptosis. ARHGAP45 is associated with signaling pathways such as those involved in cell proliferation and survival, and its dysregulation has been linked to several diseases, including cancer, neurological disorders, and cardiovascular diseases. Drug development for ARHGAP45 inhibitors is ongoing, aiming to modulate Rho GTPase activity for therapeutic benefits.
ARHGAP45 inhibitors are being explored for their potential therapeutic applications in various diseases, including cancer, neurological disorders, and cardiovascular diseases. These inhibitors aim to modulate the activity of Rho GTPases by maintaining their active state, which can lead to various cellular outcomes such as enhancing cytoskeletal dynamics and influencing signaling pathways involved in cell proliferation and survival. Despite the promising potential, further research is needed to fully understand their mechanisms, improve their specificity, and ensure their safety and efficacy in clinical settings.